Update information
March 2021: We produced a statement clarifying our recommendations on unlicensed cannabis-based medicinal products for severe treatment-resistant epilepsy, which should be read alongside the recommendations.
Minor changes since publication
May 2025: We added links to relevant technology appraisal guidance in the section on severe treatment-resistant epilepsy.
October 2022: In recommendation 1.5.1 and the March 2021 clarification statement we clarified that the initiating prescriber of cannabis-based medicinal products for children and young people under the care of paediatric services should also be a tertiary paediatric specialist in the condition being treated.
October 2021: We added a link to NICE's guideline on babies, children and young people's experience of healthcare in recommendation 1.5.6 and to NICE's guideline on shared decision making in recommendation 1.5.11.
ISBN: 978-1-4731-3578-9